| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Interest accretion expense | - | 0 | - | 4 |
| Income from continuing operations before tax | 1,000 | -533 | 1,772 | 1,366 |
| (benefit) provision for income taxes | -11 | 0 | 18 | 4 |
| Income from continuing operations | 1,011 | -533 | 1,754 | 1,362 |
| Loss from discontinued operations, net of tax | -100 | -107 | -107 | -82 |
| Net income | 911 | -640 | 1,647 | 1,280 |
| Basic | 4,425,000 | 4,423,000 | 4,420,000 | 4,393,000 |
| Diluted | 27,695,000 | 4,423,000 | 27,704,000 | 4,423,000 |
| Net income (loss) per basic share of common stock | 0.21 | -0.14 | 0.37 | 0.29 |
| Net income (loss) per diluted share of common stock | 0.03 | -0.14 | 0.06 | 0.29 |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)